Generic drugs have dramatically changed the pharmaceutical and health-care landscape in the last 25 years and now account for about 80 percent of prescriptions in the United States, with lower prices for consumers and insurers.
But a U.S. Supreme Court case scheduled for argument March 25 pits drug companies, generic and branded, against government officials who argue that prices for consumers would be even lower if those companies did not strike deals to restrain trade. Drugstore chains and health insurers back the government's side.
Today, Novo Nordisk announced that the US Supreme Court has reversed the US Court of Appeals for the Federal Circuit’s April 2010 decision. That decision dismissed generic manufacturer Caraco Pharmaceutical’s claim to change Novo Nordisk’s patent submissions regarding the combination use of repaglinide and metformin for the treatment of type 2 diabetes.